Autopsy report · NCT05400577

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

“Grantor withdrew support due to slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Fox Chase Cancer Center

Sponsor type

University, hospital or other

Conditions

Non-Small Cell Lung Cancer

Interventions

Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
  “Funding withdrawn due to inability to accrue” (65% match in meaning)
• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
  “Withdrawn due to poor accrual” (64% match in meaning)
• Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
  “Withdrawn due to low accrual” (64% match in meaning)
• Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
  “Slow accrual; closed by funder” (63% match in meaning)
• Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
  “slow accrual; insufficient funding to continue to accrue” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.